Skip to main content

Advertisement

SpringerLink
Log in

Patients With Metastatic Breast Cancer Using Bevacizumab as a Treatment: Is There Still a Role for it?

  • Breast Cancer (CI Falkson, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Over the last few decades, the angiogenesis mechanism has increasingly been studied and implicated in cancer pathophysiology. At present, it is known that angiogenesis plays a relevant role in tumor growth, and more importantly many new molecules exists can potentially interfere with this process. Bevacizumab, a humanized monoclonal antibody targeting the vascular endothelial growth factor A (VEGF-A) now commonly used in the treatment of colorectal, renal cell, and brain cancer, is the first anti-angiogenesis drug delivered in combination with chemotherapy that has consistently shown clinical efficacy in the treatment of breast cancer. Since the ECOG 2100 trial has shown that bevacizumab added to paclitaxel as a first-line treatment for advanced breast cancer nearly doubled the time to progression and tumor response rate, its approval was granted almost worldwide. However, other phase III trials revealed a smaller absolute improvement in progression-free survival (PFS) and response rates, and no trials yet have demonstrated survival enhancement which led to a great controversy and debate over the use of bevacizumab. The discrepancy between PFS and overall survival also raises the question of whether or not bevacizumab has been applied sub-optimally in some of the studies, if a predictive biomarker(s) exists to select the group of patients whom would receive the greatest benefit and what is the appropriate clinical end-point for approval and funding of new targeted agents. In this article we will review the bevacizumab mechanism of action and the clinical trials that assessed its benefit in the treatment of metastatic breast cancer (MBC).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.

    Article  PubMed  Google Scholar 

  2. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400.

    Article  PubMed  CAS  Google Scholar 

  3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  4. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801):1461–84.

    Article  PubMed  Google Scholar 

  5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.

    Article  Google Scholar 

  6. Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Pous M, et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst. 1992;84(16):1266–72.

    Article  PubMed  CAS  Google Scholar 

  7. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer Jr CE, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366–73.

    Article  PubMed  CAS  Google Scholar 

  8. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998;16(10):3439–60.

    PubMed  CAS  Google Scholar 

  9. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong Y, et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). ASCO Meeting Abstracts 2009 June 08;27(15S):543.

    Google Scholar 

  10. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.

    Article  PubMed  CAS  Google Scholar 

  11. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.

    Article  PubMed  CAS  Google Scholar 

  12. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat. 1998;52(1–3):65–77.

    Article  PubMed  CAS  Google Scholar 

  13. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812–23.

    Article  PubMed  Google Scholar 

  14. Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Luck HJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26(12):1980–6.

    Article  PubMed  CAS  Google Scholar 

  15. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26(24):3950–7.

    Article  PubMed  Google Scholar 

  16. Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol. 2000;18(12):2385–94.

    PubMed  CAS  Google Scholar 

  17. Eskens FA, Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur J Cancer. 2008;44(16):2350–6.

    Article  PubMed  CAS  Google Scholar 

  18. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76.

    Article  PubMed  CAS  Google Scholar 

  19. Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of Bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;20:4966–72.

    Article  Google Scholar 

  20. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, et al. Phase III study of Bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(20):3239–47.

    Article  PubMed  CAS  Google Scholar 

  21. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without Bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252–60.

    Article  PubMed  CAS  Google Scholar 

  22. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002;38(12):1564–79.

    Article  PubMed  CAS  Google Scholar 

  23. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150(3):815–21.

    PubMed  CAS  Google Scholar 

  24. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795–803.

    Article  PubMed  CAS  Google Scholar 

  25. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw. 2009;20(4):158–63.

    PubMed  CAS  Google Scholar 

  26. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27.

    Article  PubMed  CAS  Google Scholar 

  27. Zerbini G, Lorenzi M, Palini A. Tumor angiogenesis. N Engl J Med. 2008 author reply 764; Aug 14;359(7):763; author reply 764.

  28. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006;312(5):549–60.

    Article  PubMed  CAS  Google Scholar 

  29. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem. 1994;269(41):25646–54.

    PubMed  CAS  Google Scholar 

  30. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A. 1998;95(20):11709–14.

    Article  PubMed  CAS  Google Scholar 

  31. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255(5047):989–91.

    Article  PubMed  Google Scholar 

  32. Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem. 2001;276(29):26969–79.

    Article  PubMed  CAS  Google Scholar 

  33. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87(8):3336–43.

    PubMed  CAS  Google Scholar 

  34. Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta. 2010;1806(1):108–21.

    PubMed  CAS  Google Scholar 

  35. Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593–9.

    PubMed  CAS  Google Scholar 

  36. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23(4):792–9.

    Article  PubMed  CAS  Google Scholar 

  37. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30(5 Suppl 16):117–24.

    Article  PubMed  CAS  Google Scholar 

  38. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of Bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-Negative metastatic breast cancer. J Clin Oncol. 2011;29(32):4286–93.

    Article  PubMed  CAS  Google Scholar 

  39. Gianni L, Romieu G, Lichinitser M, et al. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Program and abstracts of the 34th Annual San Antonio Breast Cancer Symposium; December 6–10, 2011; San Antonio, Texas. Abstract S4-8.

  40. Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, et al. Sunitinib plus paclitaxel versus Bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer. 2011;11(2):82–92.

    Article  PubMed  CAS  Google Scholar 

  41. O’Shaughnessy J, Miles D, Gray RJ, Dieras V, Perez EA, Zon R, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol. 2010;28(15 SUPPL. 1);28(15 SUPPL. 1):ate of Pubaton: 20 May 2010.This important meta-analysis evaluates three randomized trials (E2100, AVADO, and RIBBON-1) in patients with MBC that received bevacizumab plus first-line chemotherapy regimens. The study documents the gain in progress-free-survival, and the lack of significant improvement in overall survival.

  42. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2010;122(1):1–7.

    Article  PubMed  CAS  Google Scholar 

  43. Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, et al. Magnitude of risks and benefits of the addition of Bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res. 2011;30:54.

    Article  PubMed  Google Scholar 

  44. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck HJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26(12):1987–92.

    Article  PubMed  CAS  Google Scholar 

  45. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, et al. Metronomic cyclophosphamide and capecitabine combined with Bevacizumab in advanced breast cancer. J Clin Oncol. 2008;26(30):4899–905.

    Article  PubMed  CAS  Google Scholar 

  46. Garcia-Saenz JA, Martin M, Calles A, Bueno C, Rodriguez L, Bobokova J, et al. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. J Chemother. 2008;20(5):632–9.

    PubMed  CAS  Google Scholar 

  47. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation. 1995;91(3):755–63.

    PubMed  CAS  Google Scholar 

  48. Yardley DA, Burris 3rd HA, Clark BL, Shipley D, Rubin M, Barton Jr J, et al. Hormonal therapy plus Bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. Clin Breast Cancer. 2011;11(3):146–52.

    Article  PubMed  CAS  Google Scholar 

  49. Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, et al. Feasibility trial of letrozole in combination with Bevacizumab in patients with metastatic breast cancer. J Clin Oncol. 2010;28(4):628–33.

    Article  PubMed  CAS  Google Scholar 

  50. De la Haba-Rodriguez JR, von Minckwitz G, Martin M. Phase III tril evaluating the addition of Bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: The Lea Study. Program and abstracts of the 34th Annual San Antonio Breast Cancer Symposium; December 6–10, 2011; San Antonio, Texas. Abstract OT3-01-15.

  51. Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, et al. Congestive heart failure risk in patients with breast cancer treated with Bevacizumab. J Clin Oncol. 2011;29(6):632–8.

    Article  PubMed  CAS  Google Scholar 

  52. Bernaards C, Hegde P, Chen D, Holmgren E, Zheng M, Jubb AM, et al. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: analysis of phase III studies. ASCO Meeting Abstracts 2010 June 14;28(15_suppl):10519.

  53. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus Bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26(28):4672–8.

    Article  PubMed  CAS  Google Scholar 

  54. Hurwitz H, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). ASCO Meeting Abstracts 2010 June 14;28(15_suppl):3039.

  55. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010;11(12):1172–83.

    Article  PubMed  CAS  Google Scholar 

  56. Mrozek E, Lustberg MB, Knopp MV, Spigos DG, Yang X, Houton LA, et al. Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI). J Clin Oncol. 2010;28(15 SUPPL. 1);28(15 SUPPL. 1):ate of Pubaton: 20 May 2010.

  57. Mancuso MR, Davis R, Norberg SM, O’Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116(10):2610–21.

    Article  PubMed  CAS  Google Scholar 

  58. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232–9.

    Article  PubMed  CAS  Google Scholar 

  59. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220–31.

    Article  PubMed  CAS  Google Scholar 

  60. Miles D, Harbeck N, Escudier B, Hurwitz H, Saltz L, Van Cutsem E, et al. Disease course patterns after discontinuation of Bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol. 2011;29(1):83–8.

    Article  PubMed  CAS  Google Scholar 

  61. Von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, et al. Integrating Bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol. 2011;22(2):301–6.

    Article  Google Scholar 

  62. Bear H., Tang Gong, Rastogi. NSABP Protocol B-40: the effect on PCR of Bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy ASCO Meeting Abstracts 2011 June Jun 23, 2011:LBA1005.

  63. Ranpura V, Hapani S, Wu S. Treatment-related mortality with Bevacizumab in cancer patients: a meta-analysis. JAMA. 2011;305(5):487–94.

    Article  PubMed  CAS  Google Scholar 

  64. Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestalozzi BC, Fink D, Brauchli P, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer. 2009;45(8):1397–406.

    Article  PubMed  CAS  Google Scholar 

  65. Montero AJ, Gluck S, Lopes GdL. The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer. ASCO Meeting Abstracts 2011 June 09;29(15_suppl):6060.

  66. Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010;121(1):121–31.

    Article  PubMed  CAS  Google Scholar 

  67. Moss J, Stevens M, Birk S, Westberry K, Romond E, Shelton B, et al. Abstract P4-02-19: a phase II study of adding the multikinase inhibitor sorafenib to existing endocrine therapy in patients with metastatic estrogen receptor positive breast cancer. Cancer Res. 2011;70(24 Supplement):P4-02-19.

    Article  Google Scholar 

  68. Luu T, Frankel P, Chung C, Mortimer J, Hurria A, Somlo G. Abstract P6-12-07: phase II trial of vinorelbine and sorafenib in Metastatic Breast Cancer (MBC). Cancer Res. 2011;70(24 Supplement):P6-12-07.

    Article  Google Scholar 

  69. Bondarde S, Kaklamani V, Prasad Sahoo T, Lokanatha D, Raina V, Jain M, et al. Abstract P2-16-03: sorafenib in combination with paclitaxel as a first-line therapy in patients with locally recurrent or metastatic breast cancer: overall survival results from a double-blind, randomized, placebo-controlled, phase 2b trial. Cancer Res. 2011;70(24 Supplement):P2-16-03.

    Article  Google Scholar 

  70. Gomez P, Roche H, Costa F, Segalla J, Pinczowski H, Ciruelos E, et al. Abstract P2-16-01: overall survival data from SOLTI-0701: a multinational, double-blind, placebo-controlled, randomized phase 2b study evaluating the oral combination of sorafenib and capecitabine in patients with locally advanced or metastatic HER2-Negative breast cancer. Cancer Res. 2011;70(24 Supplement):P2-16-01.

    Article  Google Scholar 

  71. Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, et al. Motesanib, or open-label Bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2011;12(4):369–76.

    Article  PubMed  CAS  Google Scholar 

  72. Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol. 2011;29(18):2459–65.

    Article  PubMed  CAS  Google Scholar 

  73. Phase III study of Docetaxel + Ramucirumab or placebo in breast cancer. Available at :http://www.liferaft-groups.org. Accessed December 13, 2011.

Download references

Disclosure

S. Chia: Consultancy for Hoffmann-LaRoche, received honoraria from GlaxoSmithKline, Hoffmann-LaRoche, AstraZeneca and Novartis, received payment for development of educational presentations from Hoffmann-LaRoche, AstraZeneca and GlaxoSmithKline, and had travel/accommodations expenses covered or reimbursed from Hoffmann-LaRoche and Novartis; AE Lohmann: received payment for development of educational presentations and had travel/accommodations expenses covered or reimbursed by Roche.

Author information

Authors and Affiliations

  1. British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada, V5Z 4E6

    Ana Elisa Lohmann MD & Stephen Chia MD, FRCP(C)

Authors
  1. Ana Elisa Lohmann MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen Chia MD, FRCP(C)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen Chia MD, FRCP(C).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lohmann, A.E., Chia, S. Patients With Metastatic Breast Cancer Using Bevacizumab as a Treatment: Is There Still a Role for it?. Curr. Treat. Options in Oncol. 13, 249–262 (2012). https://doi.org/10.1007/s11864-012-0181-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-012-0181-9

Keywords

Search

Navigation